Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative18f-fdg pet/ct in patients with pancreatic cancer

Journal of Nuclear Medicine

Volumn 55, Issue 6, 2014, Pages 898-904

  Lee, Jeong Won ^a   Kang, Chang Moo ^a   Choi, Hye Jin ^a   Lee, Woo Jung ^a   Song, Si Young ^a   Lee, Jae Hoon ^a   Lee, Jong Doo ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Metabolic tumor volume; Pancreatic cancer; PET; Prognosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METABOLIC TUMOR VOLUME; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TOTAL LESION GLYCOLYSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; GLYCOLYSIS; METABOLISM; MIDDLE AGED; MULTIMODAL IMAGING; PANCREATIC NEOPLASMS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; TUMOR VOLUME;

FEMALE; FLUORODEOXYGLUCOSE F18; GLYCOLYSIS; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84903118832     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.131847     Document Type: Article

References (27)

1. Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th ed. AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007;110:738-744.
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049-1057. (Pubitemid 38410779)
3. Grassetto G, Rubello D. Role of FDG-PET/CT in diagnosis, staging, response to treatment, and prognosis of pancreatic cancer. Am J Clin Oncol. 2011;34:111-114.
4. Palmer DH, Stocken DD, Hewitt H, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol. 2007;14:2088-2096. (Pubitemid 46988260)
5. Smeenk HG, van Eijck CH, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg. 2007;246:734-740. (Pubitemid 350035648)
6. Heinrich S, Goerres GW, Schäfer M, et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg. 2005;242:235-243. (Pubitemid 41033440)
7. Hata S, Sakamoto Y, Yamamoto Y, et al. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol. 2012;19:636-641.
8. Lewis R, Drebin JA, Callery MP, et al. A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. HPB (Oxford). 2013;15:49-60.
9. Kato K, Yamada S, Sugimoto H, et al. Prognostic factors for survival after extended pancreatectomy for pancreatic head cancer: influence of resection margin status on survival. Pancreas. 2009;38:605-612.
10. Asagi A, Ohta K, Nasu J, et al. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence. Pancreas. 2013;42:11-19.
11. 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg. 2009;250:957-963.
12. Okamoto K, Koyama I, Miyazawa M, et al. Preoperative 18[F]- fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection. Int J Clin Oncol. 2011;16:39-44.
13. 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol. 2011;11:123.
14. Lee SM, Kim TS, Lee JW, Kim SK, Park SJ, Han SS. Improved prognostic value of standardized uptake value corrected for blood glucose level in pancreatic cancer using F-18 FDG PET. Clin Nucl Med. 2011;36:331-336.
15. Hwang JP, Lim I, Chang KJ, Kim BI, Choi CW, Lim SM. Prognostic value of SUVmax measured by fluorine-18 fluorodeoxyglucose positron emission tomography with computed tomography in patients with pancreatic cancer. Nucl Med Mol Imaging. 2012;46:207-214.
16. 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39:925-935.
17. 18F-FDG PET/CT in salivary gland carcinomas. J Nucl Med. 2013;54:1032-1038.
18. 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med. 2013;54:1202-1208.
19. Parlak C, Topkan E, Onal C, Reyhan M, Selek U. Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy [abstract]. Radiat Oncol. 2012;7:37.
20. Davison J, Mercier G, Russo G, Subramaniam RM. PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma. AJR. 2013;200:635-640.
21. Delbeke D, Rose DM, Chapman WC, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med. 1999;40:1784-1791. (Pubitemid 29523570)
22. Kim EJ, Ben-Josef E, Herman JM, et al. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer. 2013;119:2692-2700.
23. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-277. (Pubitemid 46143304)
24. Estrella JS, Rashid A, Fleming JB, et al. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012;118:268-277.
25. Aggarwal G, Kamada P, Chari ST. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas. 2013;42:198-201.
26. Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134:95-101. (Pubitemid 350309328)
27. Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med. 1998;39:1030-1033. (Pubitemid 28270121)